ArticleAllergy, asthma & immunology research2021
Dupilumab Therapy Improves Stratum Corneum Hydration and Skin Dysbiosis in Patients With Atopic Dermatitis.
Article in Allergy, asthma & immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Restoration of Skin Barrier Abnormalities with IL4/13 Inhibitors and Jak Inhibitors in Atopic Dermatitis: A Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis.Allergy · 2026Trial
- Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.The Journal of allergy and clinical immunology · 2023Trial
- The era of advanced therapeutics for pediatric atopic dermatitis - can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?Current opinion in pediatrics · 2026Review
- Staphylococcus aureus in atopic dermatitis: How a common bacterium exploits and drives disease.The Journal of allergy and clinical immunology · 2026Review
- Association betweenFrontiers in medicine · 2026Article
- Skin Microbiome Shifts in Various Dermatological Conditions.Journal of clinical medicine · 2025Review
- Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors.Annals of dermatology · 2025Article
- The skin microbiome in dermatologic disease.Journal of the American Academy of Dermatology · 2025Review
- Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier.Clinical reviews in allergy & immunology · 2025Review
- The epidermal lipid-microbiome loop and immunity: Important players in atopic dermatitis.Journal of advanced research · 2025Review
- Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.Frontiers in immunology · 2025Article
- The Skin Microbiome and its Significance for Dermatologists.American journal of clinical dermatology · 2024Article
- Dupilumab Alters Both the Bacterial and Fungal Skin Microbiomes of Patients with Atopic Dermatitis.Microorganisms · 2024Article
- Skin microbiota: pathogenic roles and implications in atopic dermatitis.Frontiers in cellular and infection microbiology · 2024Review
- Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review.Drug design, development and therapy · 2024Review
- Altered Gene Expression of IL-35 and IL-36α in the Skin of Patients with Atopic Dermatitis.International journal of molecular sciences · 2023Article
- Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.Nature reviews. Drug discovery · 2023Review
- Targeting Skin Barrier Function in Atopic Dermatitis.The journal of allergy and clinical immunology. In practice · 2023Article
- An Overview of the Latest Metabolomics Studies on Atopic Eczema with New Directions for Study.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to investigate the effects of dupilumab on 1) the permeability and antimicrobial barrier, 2) the composition of the skin microbiome, and 3) the correlation between changes in skin barrier properties and microbiota in atopic dermatitis (AD) patients.
methodsTen patients with severe AD were treated with dupilumab for 12 weeks. Disease severity was assessed using the Eczema Area and Severity Index (EASI). Skin barrier function was evaluated by measuring transepidermal water loss, stratum corneum (SC) hydration, and pH. The following parameters were analyzed in the pre- and post-treatment SC samples; 1) skin microbiota using 16S rRNA gene sequencing, 2) lipid composition using mass spectrometry, and 3) human β-defensin 2 (hBD-2) expression using quantitative reverse transcription polymerase chain reaction.
resultsSC hydration levels in the lesional and non-lesional skin increased after 12-week dupilumab therapy (24.2%,
conclusionsTh2 blockade-induced normalization of skin microbiome in AD patients is associated with increased SC hydration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.